Screening for Osteoporosis to Prevent Fractures
JAMA · 11.02.2025 · 333 (6) · 509
DOI: 10.1001/jama.2024.21653 ↗Kurz gefasst
Metaanalyse in der Zeitschrift JAMA, erschienen am 11.02.2025. Verfasst von Leila C Kahwati und 7 weiteren Autor:innen. Beteiligte Einrichtung: RTI International-University of North Carolina at Chapel Hill Evidence-based Practice Center. Hauptthemen laut MEDLINE: Mass Screening, Osteoporosis, Osteoporotic Fractures, Preventive Health Services. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 216 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, AHRQ HHS.
Abstract (Originalsprache)
Importance Fragility fractures result in significant morbidity.
Objective
To review evidence on osteoporosis screening to inform the US Preventive Services Task Force. Data Sources PubMed, Embase, Cochrane Library, and trial registries through January 9, 2024; references, experts, and literature surveillance through July 31, 2024. Study Selection Randomized clinical trials (RCTs) and systematic reviews of screening; pharmacotherapy studies for primary osteoporosis; predictive and diagnostic accuracy studies. Data Extraction and Synthesis Two reviewers assessed titles/abstracts, full-text articles, study quality, and extracted data; when at least 2 similar studies were available, meta-analyses were conducted. Main Outcomes and Measures Hip, clinical vertebral, major osteoporotic, and total fractures; mortality; harms; accuracy.
Results
Three RCTs and 3 systematic reviews reported benefits of screening in older, higher-risk women. Two RCTs used 2-stage screening: Fracture Risk Assessment Tool estimate with bone mineral density (BMD) testing if risk threshold exceeded. One RCT used BMD plus additional tests. Screening was associated with reduced hip (pooled relative risk [RR], 0.83 [95% CI, 0.73-0.93]; 3 RCTs; 42 009 participants) and major osteoporotic fracture (pooled RR, 0.94 [95% CI, 0.88-0.99]; 3 RCTs; 42 009 participants) compared with usual care. Corresponding absolute risk differences were 5 to 6 fewer fractures per 1000 participants screened. The discriminative accuracy of risk assessment instruments to predict fracture or identify osteoporosis varied by instrument and fracture type; most had an area under the curve between 0.60 and 0.80 to predict major osteoporotic fracture, hip fracture, or both. Calibration outcomes were limited. Compared with placebo, bisphosphonates (pooled RR, 0.67 [95% CI, 0.45-1.00]; 6 RCTs; 12 055 participants) and denosumab (RR, 0.60 [95% CI, 0.37-0.97] from the largest RCT [7808 participants]) were associated with reduced hip fractures. Compared with placebo, no statistically significant associations were observed for adverse events. Conclusions and Relevance Screening in higher-risk women 65 years or older was associated with a small absolute risk reduction in hip and major fractures compared with usual care. No evidence evaluated screening with BMD alone or screening in men or younger women. Risk assessment instruments, BMD alone, or both have poor to modest discrimination for predicting fracture. Osteoporosis treatment with bisphosphonates or denosumab over several years was associated with fracture reductions and no meaningful increase in adverse events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- RTI International-University of North Carolina at Chapel Hill Evidence-based Practice Center.
- RTI International, Research Triangle Park, North Carolina.
- Division of Geriatric Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
- Department of Internal Medicine, The Ohio State University College of Medicine, Columbus.
- Department of Family Medicine and Community Health, University of Minnesota Medical School, Minneapolis.
Förderung
- NCATS NIH HHS
- AHRQ HHS
Zitieren
APA
Kahwati, L. C., Kistler, C. E., Booth, G., Sathe, N., Gordon, R. D., Okah, E., Wines, R. C., & Viswanathan, M. (2025). Screening for Osteoporosis to Prevent Fractures. JAMA, 333(6), 509. https://doi.org/10.1001/jama.2024.21653
Vancouver
Kahwati LC, Kistler CE, Booth G, Sathe N, Gordon RD, Okah E, et al. Screening for Osteoporosis to Prevent Fractures. JAMA. 2025;333(6):509. doi:10.1001/jama.2024.21653
BibTeX
@article{Kahwati2025,
author = {Kahwati, Leila C and Kistler, Christine E and Booth, Graham and Sathe, Nila and Gordon, Rachel D'Amico and Okah, Ebiere and Wines, Roberta C and Viswanathan, Meera},
title = {Screening for Osteoporosis to Prevent Fractures},
journal = {JAMA},
year = {2025},
volume = {333},
number = {6},
pages = {509},
doi = {10.1001/jama.2024.21653}
}
EUVIMED